Study of a new imaging agent for breast and lung cancers
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new imaging agent called [68Ga]Ga-DWJ155 to see how well it helps detect certain types of advanced breast cancer and non-small cell lung cancer. It may help doctors better understand the cancer and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these cancer types: certain advanced breast cancer (HR+/HER2- or HER2+) or advanced non-small cell lung cancer (adenocarcinoma type).
- Your cancer must be advanced (spread or cannot be removed by surgery) and you either haven't had treatment yet, are on your first line of therapy, or have had previous treatment (for HER2+ breast cancer).
- You must have at least one tumor that can be measured on a CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This trial tests a new imaging agent called 68Ga-JH04 that is used with a PET/CT scan. The goal is to see how the agent travels through the body and how much radiation it gives off, which may help doctors better understand and treat your tumor.
This early-stage trial tests a new experimental drug called HT547 that combines radioactive tracers to help doctors see and treat certain solid tumors (breast, head and neck, pancreatic, or brain cancer). The study will check if the drug is safe, how it moves through your body, and how much radiation it gives you.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.